NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares at an exercise price of $1.75 per share, with a three-year term. Closing is expected on or about May 18, 2026, subject to customary conditions. The full press release provides further details.
This capital raise is significant for NanoViricides as it continues to advance NV-387, a clinical-stage, broad-spectrum antiviral drug based on host-mimetic nanomedicine technology. NV-387 has received Orphan Drug Designation from the U.S. FDA Office of Orphan Products Development, which could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. The drug is designed to target respiratory viral illnesses and has demonstrated high effectiveness in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
The offering underscores investor confidence in NanoViricides' approach to developing antivirals that viruses and their variants cannot escape. The proceeds will likely support ongoing clinical trials and further development of NV-387, which the company believes could become a first-line treatment for patients presenting with respiratory viral infections. This funding comes at a critical time as the world continues to grapple with emerging viral threats and the need for broad-spectrum antiviral therapies.
For more information about NanoViricides and its pipeline, visit the company's newsroom at https://ibn.fm/NNVC. This announcement highlights the company's progress in addressing unmet medical needs in antiviral therapy and its potential to impact public health.
